June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
ICE-UK - The evaluation of the fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular edema (DME) in NHS clinical practice
Author Affiliations & Notes
  • Daniela Collins
    Ophthalmology, James Cook University Hospital , Durham, United Kingdom
  • Footnotes
    Commercial Relationships   Daniela Collins, Alimera (R), Alimera (C)
  • Footnotes
    Support  Bayer travel grant
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 925. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Daniela Collins; ICE-UK - The evaluation of the fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular edema (DME) in NHS clinical practice. Invest. Ophthalmol. Vis. Sci. 2017;58(8):925.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : ILUVIEN slowly releases fluocinolone acetonide (FAc) and leads to continuous, sustained improvements in retinal anatomy and function lasting for up to 36 months. Controlled collection of real-world data is still quite limited. ICE (ILUVIEN Clinical Evaluation)-UK evaluated the effectiveness of ILUVIEN in routine clinical practice in the UK in patient eyes insufficiently responsive to other DME treatments.

Methods : A retrospective, observational cohort study (n=186 eyes from n=170 patients) with non-treatment naïve DME. Patients were treated at 12 UK hospitals and data was collected in the 12 months prior to and 12 months following the intravitreal injection of ILUVIEN.

Results : Prior treatment included ranibizumab (74%) of eyes; triamcinolone (40%); and bevacizumab (27%). At implantation 91% eyes were pseudophakic. Median visual acuity (VA) was 52 ETDRS letters (interquartile range [IQR], 35-60), median central subfield thickness (CST) was 464 microns (IQR range, 363-599) and median IOP was 15 mmHg (IQR range, 13-18). At 3 months, 45% of treated eyes gained ≥5 ETDRS letters; 30% gained ≥10; and 17% ≥15. These improvements were sustained through month 12 with 45% of treated eyes gaining d ≥5 letters; 32% ≥10; and 21% ≥15. Increase in intraocular pressure (IOP) was observed in 15% of treated eyes by 12 months, and two eyes (1.1%) required IOP-related surgery.

Conclusions : Real-world data from eyes with DME that were deemed to be insufficiently responsive to other therapies experienced improvements in VA after treatment with ILUVIEN and this was sustained through month 12. One fifth of treated eyes improved by at least 15 letters at 12 months and the rate of adverse events were low.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×